Loading…
CytoMed Therapeutics Limited is projected to rise to $1.27 by 2027, a +6% move from its current price of $1.20. GDTC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.13 | $1.20 | $1.27 | +0.07% |
| May 30 | $1.11 | $1.20 | $1.31 | +0.14% |
| May 31 | $1.09 | $1.20 | $1.33 | +0.21% |
| Jun 1 | $1.07 | $1.20 | $1.35 | +0.28% |
| Jun 2 | $1.06 | $1.20 | $1.37 | +0.36% |
| Jun 3 | $1.04 | $1.21 | $1.39 | +0.43% |
| Jun 4 | $1.03 | $1.21 | $1.41 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.03 | $1.21 | $1.41 | +0.50% |
| Week 2 | $0.9731 | $1.21 | $1.51 | +1.00% |
| Week 3 | $0.9309 | $1.22 | $1.59 | +1.50% |
| Week 4 | $0.8974 | $1.22 | $1.67 | +2.01% |
| Week 5 | $0.8695 | $1.23 | $1.74 | +2.52% |
| Week 6 | $0.8453 | $1.24 | $1.81 | +3.03% |
| Week 7 | $0.8241 | $1.24 | $1.87 | +3.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytoMed Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, CTM-GDT, and CTM-MSC, and has research collaboration agreements with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trials in Singapore, and with SunAct Cancer Institute Private Limited to conduct clinical trials for GMP-grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
GDTC is currently priced at $1.13 per share, with a market capitalization of $13.37M, and it is ranked 5069 by market cap. The stock’s price action is supported by technicals showing the 50-day simple moving average at $1.01 and the 200-day simple moving average at $1.49, with the current price trading above the 50-day SMA but below the 200-day SMA.
Near term, the stock bears a bullish sentiment with RSI-14 at 60. The price has a defined 30-day range, between $0.7531 and $1.70, with a near-term support at $0.723 and resistance at $1.32.
A major floor 59.7% below — a decisive break under it would weaken the trend.
The nearest floor, 39.8% below — buyers have tended to step in here.
The nearest ceiling, 10.0% above — a clean break opens room to run.
A major ceiling 39.8% above — clearing it would confirm fresh momentum.
Key GDTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GDTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.20 | Sell | $1.17 | Buy |
| MA 10 | $1.12 | Buy | $1.12 | Buy |
| MA 20 | $1.01 | Buy | $1.06 | Buy |
| MA 50 | $1.01 | Buy | $1.04 | Buy |
| MA 100 | $1.03 | Buy | $1.14 | Buy |
| MA 200 | $1.48 | Sell | $1.40 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.80 | Neutral |
| Stoch RSI (14) | 75.65 | Neutral |
| CCI (20) | 83.33 | Neutral |
| Williams %R (14) | -20.10 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 53.85 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 79.90 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.20 | Buy |
| Ultimate (7,14,28) | 56.97 | Neutral |
| Momentum (10) | 0.43 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 1.18 | Buy |
| ADX (14) | 19.79 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day price action spans from $0.7531 to $1.70, indicating a relatively broad trading band for CytoMed Therapeutics Limited over the past month.
RSI(14) is 60 and the market sentiment is BULLISH, with the price currently above the $1.01 50-day SMA and below the $1.49 200-day SMA. Key near-term levels are support at $0.723 and resistance at $1.32, framing a cautious but constructive short-term outlook.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.723 | $1.20 | $1.75 | 0% | Neutral | |
| $0.916 | $1.27 | $1.91 | +6% | Neutral | |
| $0.8838 | $1.30 | $2.08 | +9% | Neutral | |
| $0.931 | $1.45 | $2.42 | +20% | Bullish | |
| $1.29 | $2.09 | $3.64 | +74% | Bullish | |
| $1.55 | $2.63 | $4.75 | +119% | Bullish | |
| $1.31 | $2.32 | $4.31 | +93% | Bullish | |
| $1.22 | $2.26 | $4.31 | +88% | Bullish | |
| $1.27 | $2.44 | $4.79 | +104% | Bullish | |
| $1.23 | $2.45 | $4.90 | +104% | Bullish | |
| $1.64 | $3.65 | $8.03 | +204% | Bullish | |
| $4.36 | $9.68 | $22.26 | +707% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.723 | $1.20 | $1.43 | +0.00% |
| June 2026 | $1.06 | $1.28 | $1.59 | +6.43% |
| July 2026 | $1.05 | $1.28 | $1.63 | +0.26% |
| August 2026 | $0.9743 | $1.20 | $1.56 | -5.95% |
| September 2026 | $0.9818 | $1.23 | $1.62 | +1.90% |
| October 2026 | $1.04 | $1.31 | $1.75 | +6.59% |
| November 2026 | $1.01 | $1.29 | $1.75 | -1.17% |
| December 2026 | $0.9952 | $1.28 | $1.75 | -1.06% |
Click any year to see its month-by-month GDTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GDTC could reach as high as $1.75, with a base case around $1.20 and support toward $0.723 — roughly 0% from $1.20. A consolidation phase looks the most probable path here.
Expect GDTC to range from $0.916 to $1.91 through 2027. The $1.27 average target implies a +6% move from current prices. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
The GDTC price prediction for 2028 points to an average of $1.30 (low $0.8838, high $2.08) — a potential gain of +9% on today's $1.20. A consolidation phase looks the most probable path here.
In 2029, GDTC is projected to trade between $0.931 and $2.42, averaging $1.45 — a potential gain of +20% from today's $1.20. That is up +11% on the projected 2028 average. Momentum favours further upside here.
CytoMed Therapeutics Limited's 2030 outlook centres on $2.09, within a $1.29 to $3.64 range. That is up +45% on the projected 2029 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GDTC could reach as high as $4.75, with a base case around $2.63 and support toward $1.55 — roughly +119% from $1.20. Momentum favours further upside here.
Expect GDTC to range from $1.31 to $4.31 through 2032. The $2.32 average target implies a +93% move from current prices. That is -12% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The GDTC price prediction for 2033 points to an average of $2.26 (low $1.22, high $4.31) — a potential gain of +88% on today's $1.20. Momentum favours further upside here.
In 2034, GDTC is projected to trade between $1.27 and $4.79, averaging $2.44 — a potential gain of +104% from today's $1.20. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
CytoMed Therapeutics Limited's 2035 outlook centres on $2.45, within a $1.23 to $4.90 range. That is up 0% on the projected 2034 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2040, GDTC could reach as high as $8.03, with a base case around $3.65 and support toward $1.64 — roughly +204% from $1.20. Buyers look set to stay in control over this stretch.
Expect GDTC to range from $4.36 to $22.26 through 2050. The $9.68 average target implies a +707% move from current prices. That is up +165% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GDTC today (≈ 833.333333 GDTC) could be worth
$8,066.94
+$7,066.94 (+707%) by 2050 · US Dollar
Based on the average projected GDTC price of $9.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GDTCwould be worth at today's price.
$1,000 invested in GDTC on May 27, 2025 (≈ 420.168047 GDTC) would be worth
$504.2
-$495.8 (-49.6%) today · 0.50× · US Dollar
Based on a GDTC entry price of $2.38 vs. today's $1.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.32 | $909.09 | -9.1% |
| 1 month ago | $0.98 | $1,224.49 | +22.4% |
| 3 months ago | $1.08 | $1,111.11 | +11.1% |
| 6 months ago | $1.84 | $652.17 | -34.8% |
| 1 year ago | $2.38 | $504.2 | -49.6% |
| All time (3.1y) ago | $4 | $300 | -70.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GDTC forecast.
Our base-case forecast reaches $2.40 around 2031.
Implied market cap at $2.40: $28.4M
The multi-year forecast shows a clear bullish tilt beginning in 2030, with an average price of $1.68, a minimum of $1.03, a maximum of $2.93 and a projected return on investment of 48.6%, signaling meaningful upside as the horizon extends.
By 2040 the average is $2.61 with a min of $1.18 and a max of $5.75, and a forecast ROI of 131.2%, reflecting substantial long-term appreciation alongside rising volatility.
In 2050 the average is $6.78, with a min of $3.05 and a max of $15.60, offering a forecast ROI of 500.4% and a bullish sentiment. The figures imply significant upside potential but also highlight the high volatility environment, supported by an annualized volatility of 100%.
Overall, the outlook points to strong long-term upside with heightened risk, as reflected in the high volatility and the expansive max price in 2050.
Tap a question to reveal the answer.
Avg $1.68, min $1.03, max $2.93, ROI 48.6%, sentiment BULLISH.
The long-term forecast shows bullish sentiment and upside through 2050 (avg $6.78, max $15.60, ROI 500.4%), but these are estimates and not guarantees.
Yes. The forecast shows a max price of $5.75 in 2040 and $15.60 in 2050.
Current price is $1.13 and market cap is $13.37M.
Low $0.7531, High $1.70.
CytoMed Therapeutics Limited Community Discussion
0Share your CytoMed Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.